Investment Rating - The investment rating for the company is "Accumulate" [5][11]. Core Views - The company experienced a decline in revenue and net profit in the first half of 2025, with total revenue of 16.743 billion yuan, down 18.45% year-on-year, and net profit of 5.069 billion yuan, down 32.96% year-on-year. The gross margin decreased by 4.98 percentage points [1][5]. - International business showed resilience with revenue of 8.333 billion yuan in H1 2025, up 5.39% year-on-year, accounting for 49.76% of total revenue. Domestic revenue, however, fell to 8.411 billion yuan, down 33.37% year-on-year [1][2]. - The company plans to distribute a total cash dividend of 3.298 billion yuan for 2025, which represents 65.06% of the net profit for the first half of the year [2]. Summary by Sections Financial Performance - In Q2 2025, the company reported revenue of 8.506 billion yuan, a decrease of 23.77% year-on-year, and a net profit of 2.440 billion yuan, down 44.55% year-on-year, with a gross margin decline of 5.66 percentage points [1][5]. - The medical imaging business generated revenue of 3.312 billion yuan, down 22.51% year-on-year, with international revenue accounting for 62% [2]. - The life information and support business reported revenue of 5.479 billion yuan, down 31.59%, with international revenue share increasing to 67% [2]. Future Projections - Revenue projections for 2025-2027 are 36.730 billion yuan, 41.909 billion yuan, and 48.457 billion yuan, with year-on-year growth rates of 0.0%, 14.1%, and 15.6% respectively. Net profit projections are 12.219 billion yuan, 14.156 billion yuan, and 16.633 billion yuan, with growth rates of 4.7%, 15.8%, and 17.5% respectively [3][10].